Please assess the completion status of the following clinical trial:

Trial Title: AnaConDa-therapy in COVID-19 Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* More than 24 hours of invasive mechanical ventilation needed~* Positive test (e.g. Polymerase Chain Reaction (PCR)) for SARS-CoV-2~Exclusion Criteria:~* pulmonary history~* known allergy or hypersensitivity for halogenated anesthetics~* known or suspected predisposition for malignant hyperthermia~* suspected or proven intracranial hypertension~* severe liver dysfunction and/or icterus (serum bilirubin \>42,8-51,3 μg per liter)~* neutropenia (\<0.5X10\^9 neutrophils per liter)~* chemotherapy in the month prior to ICU admission~* patients that are transported to other hospitals during admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevoflurane (Type: None): patients admitted because of respiratory insufficiency due to COVID-19 with need for invasive mechanical ventilation that are sedated by using sevoflurane
- Control (Type: None): patients admitted because of respiratory insufficiency due to COVID-19 with need for invasive mechanical ventilation that are sedated by means of intravenous medication, such as propofol, midazolam, esketamine of fentanyl

Based on this trial design, predict the completion outcome and termination type (if applicable).